1. Dose and dose intensity of adjuvant chemotherapy for stage II, node‐positive breast carcinoma;Wood;N Engl J Med,1994
2. O'Shaughnessy JA, Noone MH, Gossard M., Venzon DJ, Denicoff AM, Tolcher A., Goldspiel B., Keegan P., Miller L., Cowan KH. Sequential interleukin‐3 (IL‐3) and granulocyte‐macrophage colony stimulating factor (GM‐CSF) is superior to either cytokine alone in ameliorating FLAC (5‐fluorouracil, leukovorin, doxorubicin, cyclophosphamide)‐induced myelosuppression. In: Program and Proceedings of the 30th Annual Meeting of the American Society of Clinical Oncology; May 14–17, 1994; Dallas, TX 1994; 344a.
3. Recombinant granulocyte‐macrophage colony‐stimulating factor after autologous bone marrow transplantation for lymphoid cancer;Nemunaitis;N Engl J Med,1991
4. Granulocyte colony‐stimulating factor and neutrophil recovery after high‐dose chemotherapy and autologous bone marrow transplantation;Sheridan;Lancet,1989
5. Vose JM, Anderson J., Bierman PJ, Garrison L., Appelbaum F., Anderson JR, Bishop M., Larsen K., Armitage JO. Initial trial of PIXY321 (GM‐CSF/IL‐3 fusion protein) following high‐dose chemotherapy and autologous bone marrow transplantation (ABMT) for lymphoid malignancy. In: Program and Proceedings of the 29th Annual Meeting of the American Society of Clinical Oncology; May 16–18, 1993; Orlando, FL 1993: 1237a.